CEoT Lunch Symposium
Sponsored by Natera
Saturday, Feb. 27
1:30 – 2:45pm (EST)
Molecular-level Insights in Kidney Transplant Care: Prospera Deep Dive
Personalized care with Prospera
Longitudinal monitoring of anti-rejection therapy with independent assessment using Prospera and background cfDNA
This session explores the new applications of cell-free and genomic DNA in renal transplant care management, including new data on over 1,300+ patients and in anti-rejection therapy surveillance . Transplant physicians will share their experiences incorporating Prospera into their routine care protocols.
- Hear how your transplant colleagues are incorporating Prospera into their routine care protocols
- Preview early data on the use of donor-derived cell-free DNA in over 1,300+ kidney recipients
- Learn why background cfDNA impacts your protocol for assessing immunosuppression therapy
This is not an official function of the CEoT Meeting and is not endorsed by AST.